UAE Investment in Genomics and AI Propels Middle East Biopharma Innovation
Strategic investments in precision medicine, artificial intelligence and advanced manufacturing position the UAE as a catalyst for transformative growth across the region's pharmaceutical sector.
The United Arab Emirates is establishing itself as the driving force behind a fundamental transformation of the Middle East’s biopharmaceutical landscape. Through substantial national investment in genomics, artificial intelligence and advanced manufacturing capabilities, the nation is reshaping the discovery, development and production of medicines across the entire region.
According to a comprehensive report from World Health Expo in partnership with Frost & Sullivan, the Middle East is poised for precision medicine growth exceeding ten percent over the next five to seven years, mirroring the expansion trajectory observed in developed markets. This expansion reflects the emergence of an increasingly integrated regional ecosystem, seamlessly connecting genomics research, next-generation therapies, artificial intelligence-enabled drug development and local manufacturing infrastructure.
The scale of investment currently underway throughout the UAE underscores this strategic pivot. The Emirati Genome Program is systematically collecting one million genetic samples nationwide, whilst the UAE Reference Genome study continues to analyse more than fifty thousand genome samples. These initiatives are constructing essential infrastructure to support disease prevention, precision treatments and advanced healthcare research capabilities.
Abu Dhabi’s Health, Endurance, Longevity and Medicine cluster represents an ambitious economic endeavour, projected to attract more than AED42 billion in investment, contribute over AED94 billion to Abu Dhabi’s GDP, and generate approximately thirty thousand employment opportunities by 2045. Encompassing biotechnology, pharmaceutical manufacturing, genomics and artificial intelligence, this cluster embodies the UAE’s comprehensive vision for developing end-to-end biopharma capabilities.
The localisation of pharmaceutical manufacturing has emerged as a strategic imperative. The 2025 launch of Mubadala Bio strengthens local manufacturing and pharmaceutical logistics infrastructure throughout the UAE. Simultaneously, the nation is advancing artificial intelligence-driven drug discovery and precision medicine. In 2025, Insilico Medicine’s Abu Dhabi centre nominated the UAE’s first fully artificial intelligence-discovered preclinical candidates for oncology and non-opioid pain applications, completing comprehensive discovery workflows within twelve months.
A significant partnership established in June 2026 between the Department of Health – Abu Dhabi and Boehringer Ingelheim aims to leverage Abu Dhabi’s expanding genomics infrastructure to advance precision-medicine research initiatives. Analysts anticipate that expanding local patient databases will generate substantial opportunities for regional and local disease modelling and drug discovery throughout the next decade and beyond.
The findings underscore how healthcare reforms and national strategies centring on biotechnology, artificial intelligence, digital infrastructure and pharmaceutical manufacturing are driving the region’s anticipated expansion. The World Health Expo 2027 will showcase this momentum, introducing dedicated Pharma and Biotech zones connecting manufacturers, contract development organisations, suppliers and technology providers. The event will welcome more than ninety thousand attendees, four thousand two hundred exhibitors and representatives from over one hundred ninety-five countries across January 25th to 28th, 2027.
Source: WAM